Spinocerebellar Ataxia (SCA)

Spinocerebellar Ataxia (SCA) is a group of hereditary neurodegenerative disorders that primarily affect the cerebellum and its connections with the spinal cord and brainstem. Since the cerebellum coordinates movement, balance, and fine motor skills, the hallmark of SCA is ataxia — uncoordinated movement. Unlike ALS or Multiple Sclerosis (MS), SCA’s core problem is cerebellar degeneration rather than motor neuron loss or immune-mediated myelin damage.

Overview

SCA results from various gene mutations, each subtype involving different genes but leading to progressive cerebellar neuron degeneration. Patients develop worsening balance and coordination issues, often with other neurological symptoms. Most cases begin in adulthood (ages 20–40), though onset and severity vary by subtype.

Types

Over 40 subtypes are known, numbered (SCA1, SCA2, SCA3, etc.), each linked to specific mutations. Common examples:

• SCA1
  • Gene: ATXN1 (CAG repeat expansion)
  • Symptoms: ataxia, slurred speech, abnormal muscle tone
• SCA2
  • Gene: ATXN2 (CAG repeat expansion)
  • Symptoms: slow movements, eye movement abnormalities, mild cognitive impairment
• SCA3 (Machado-Joseph Disease)
  • Gene: ATXN3 (CAG repeat expansion)
  • Symptoms: ataxia, muscle spasms, eyelid drooping, Parkinson-like features in late stages
  • Most common subtype
• SCA6
  • Gene: CACNA1A (CAG repeat expansion)
  • Symptoms: mild ataxia, nystagmus, slow progression
• SCA7
  • Gene: ATXN7 (CAG repeat expansion)
  • Symptoms: ataxia with retinal degeneration → vision loss

Other subtypes (e.g., SCA17) may involve cognitive decline or psychiatric symptoms.

Symptoms

Core features:

• Ataxia: unsteady gait (“drunken walk”), frequent falls
• Fine motor difficulty: trouble writing, buttoning clothes
• Speech/swallowing problems: slurred speech, dysphagia
• Eye abnormalities: nystagmus, slow eye movements, double vision
• Other possible symptoms: muscle stiffness/spasms, sensory loss, late-stage cognitive/emotional issues
• Progressive worsening due to cerebellar atrophy

Causes

• Inheritance: Most SCAs are autosomal dominant (50% chance if one parent carries the mutation).
• Gene mutations: Often due to abnormal expansion of trinucleotide repeats (CAG), similar to Huntington’s disease. This produces toxic proteins (e.g., Ataxin) that damage cerebellar neurons.
• Anticipation: Repeat expansions may increase across generations, causing earlier onset and more severe symptoms.
• Some rare subtypes (e.g., SCA36) involve other mechanisms, but cerebellar degeneration remains central.

Diagnosis

• Genetic testing: confirms subtype-specific mutations (e.g., ATXN1 repeat count)
• Neuroimaging (MRI): shows cerebellar atrophy
• Clinical evaluation: observes ataxia, eye movement abnormalities
• Family history: supports hereditary nature
• Rule out other causes (stroke, alcohol toxicity, vitamin E deficiency)

Treatment

No cure; management focuses on symptom relief and maintaining function:

1. Symptom management
   • Physical therapy: improve balance/coordination
   • Speech therapy: address speech/swallowing issues
   • Medications:
     • Muscle spasms: Baclofen, Tizanidine
     • Tremors: Propranolol, anti-seizure drugs
     • Taltirelin: approved in Japan for SCA
2. Supportive care
   • Mobility aids (walkers, wheelchairs)
   • Occupational therapy for daily living adaptation
3. Experimental therapies
   • Gene silencing (RNA interference) to reduce abnormal protein production
   • Drug trials (e.g., Riluzole, used in ALS, tested in SCA)

Prognosis

• Progression speed varies: SCA6 is slower, SCA3 faster
• Lifespan: early-onset subtypes (SCA1, SCA2) may shorten life; late-onset forms less severe
• Death often due to pneumonia or choking in advanced cases
• Quality of life depends on symptom management and support

Differences from Other Disorders

• SCA vs. ALS: SCA affects cerebellum (coordination); ALS affects motor neurons (strength).
• SCA vs. MS: SCA is genetic and degenerative; MS is immune-mediated with relapses/remissions.
• SCA vs. Parkinson’s disease: SCA causes ataxia; Parkinson’s causes tremor and rigidity.

Latest Developments

• Gene therapy: RNA interference and CRISPR approaches under study to suppress repeat expansions
• Biomarkers: blood/imaging markers for early diagnosis
• Patient registries: global databases to support clinical trials

Update: 1/5/2026